BiVictriX Therapeutics PLC - Macclesfield, England-based drug development company specialising in cancer treatments - Will raise GBP7.5 million in initial public offering on London's AIM market next month. Prices IPO at 20 pence per share, giving a market capitalisation of GBP13.2 million. Only 21% of shares will not be in public hands on admission, which is expected to be in early August. BiVictriX uses its Bi-Cygni technology to develop bispecific therapeutics. The technology uses antibody drug conjugates for the treatment of various cancers including acute myeloid leukaemia.
By Tom Waite; thomaslwaite@alliancenews.com
Copyright 2021 Alliance News Limited. All Rights Reserved.